Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00474773|
Recruitment Status : Completed
First Posted : May 17, 2007
Last Update Posted : April 28, 2016
This study will evaluate the benefits of continuing celecoxib through six weeks of total knee arthroplasty recovery. This is a randomized, double blind study with a group of approximately 130 primary total knee patients. All patients will receive celecoxib throughout their hospitalization as per current minimally invasive total knee arthroplasty protocol. At the time of hospital discharge, participating patients will be randomly placed on either celecoxib 200mg twice a day or a placebo twice a day.
This study will determine if the continued use of celecoxib for six weeks after total knee arthroplasty hospitalization will further decrease narcotic consumption, improve knee range of motion, improve ambulatory ability, and improve patient satisfaction over patients receiving celecoxib only during the acute hospitalization.
|Condition or disease||Intervention/treatment||Phase|
|Pain Management Function Minimally Invasive Total Knee Arthroplasty Celecoxib||Drug: Celecoxib||Phase 4|
|Study Type :||Observational|
|Actual Enrollment :||107 participants|
|Official Title:||Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery: A Randomized Controlled Study|
|Study Start Date :||June 2007|
|Primary Completion Date :||December 2009|
|Study Completion Date :||December 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00474773
|United States, Missouri|
|DePaul Health Center|
|St. Louis, Missouri, United States, 63044|
|Principal Investigator:||William C Schroer, MD||St. Louis Joint Replacement Institute|